PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.

Abstract CpG oligodeoxynucleotides (CpG-ODN) are being investigated as cancer vaccine adjuvants because they mature plasmacytoid dendritic cells (PDC) into potent antigen-presenting cells. CpG-ODN also induce PDC to secrete chemokines that alter lymphocyte migration. Whether CpG-ODN TLR signals enhance antigen-specific immunity and/or trafficking in humans is unknown.
PMID
Related Publications

Enhanced tumor-specific long-term immunity of hemagglutinating correction of hemaggluttinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.

Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12.

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.

CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.

CpG-independent synergistic induction of beta-chemokines and a dendritic cell phenotype by orthophosphorothioate oligodeoxynucleotides and granulocyte-macrophage colony-stimulating factor in elutriated human primary monocytes.

Authors

Mayor MeshTerms
Keywords
Journal Title clinical cancer research : an official journal of the american association for cancer research
Publication Year Start
%A Haining, W. Nicholas; Davies, Jeffrey; Kanzler, Holger; Drury, Linda; Brenn, Thomas; Evans, John; Angelosanto, Jill; Rivoli, Steven; Russell, Kate; George, Suzanne; Sims, Paul; Neuberg, Donna; Li, Xiaochun; Kutok, Jeffrey; Morgan, Jeffrey; Wen, Patrick; Demetri, George; Coffman, Robert L.; Nadler, Lee M.
%T CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.
%J Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 14, no. 17, pp. 5626-5634
%D 09/2008
%V 14
%N 17
%M eng
%B CpG oligodeoxynucleotides (CpG-ODN) are being investigated as cancer vaccine adjuvants because they mature plasmacytoid dendritic cells (PDC) into potent antigen-presenting cells. CpG-ODN also induce PDC to secrete chemokines that alter lymphocyte migration. Whether CpG-ODN TLR signals enhance antigen-specific immunity and/or trafficking in humans is unknown.
%K Adjuvants, Immunologic, Cancer Vaccines, Cell Movement, Dendritic Cells, Granulocyte-Macrophage Colony-Stimulating Factor, Humans, Oligodeoxyribonucleotides, T-Lymphocytes, Telomerase, Toll-Like Receptor 9, Vaccines, Subunit
%P 5626
%L 5634
%Y 10.1158/1078-0432.CCR-08-0526
%W PHY
%G AUTHOR
%R 2008.......14.5626H

@Article{Haining2008,
author="Haining, W. Nicholas
and Davies, Jeffrey
and Kanzler, Holger
and Drury, Linda
and Brenn, Thomas
and Evans, John
and Angelosanto, Jill
and Rivoli, Steven
and Russell, Kate
and George, Suzanne
and Sims, Paul
and Neuberg, Donna
and Li, Xiaochun
and Kutok, Jeffrey
and Morgan, Jeffrey
and Wen, Patrick
and Demetri, George
and Coffman, Robert L.
and Nadler, Lee M.",
title="CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.",
journal="Clinical cancer research : an official journal of the American Association for Cancer Research",
year="2008",
month="Sep",
day="01",
volume="14",
number="17",
pages="5626--5634",
keywords="Adjuvants, Immunologic",
keywords="Cancer Vaccines",
keywords="Cell Movement",
keywords="Dendritic Cells",
keywords="Granulocyte-Macrophage Colony-Stimulating Factor",
keywords="Humans",
keywords="Oligodeoxyribonucleotides",
keywords="T-Lymphocytes",
keywords="Telomerase",
keywords="Toll-Like Receptor 9",
keywords="Vaccines, Subunit",
abstract="CpG oligodeoxynucleotides (CpG-ODN) are being investigated as cancer vaccine adjuvants because they mature plasmacytoid dendritic cells (PDC) into potent antigen-presenting cells. CpG-ODN also induce PDC to secrete chemokines that alter lymphocyte migration. Whether CpG-ODN TLR signals enhance antigen-specific immunity and/or trafficking in humans is unknown.",
issn="1078-0432",
doi="10.1158/1078-0432.CCR-08-0526",
url="http://www.ncbi.nlm.nih.gov/pubmed/18765557",
language="eng"
}

%0 Journal Article
%T CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.
%A Haining, W. Nicholas
%A Davies, Jeffrey
%A Kanzler, Holger
%A Drury, Linda
%A Brenn, Thomas
%A Evans, John
%A Angelosanto, Jill
%A Rivoli, Steven
%A Russell, Kate
%A George, Suzanne
%A Sims, Paul
%A Neuberg, Donna
%A Li, Xiaochun
%A Kutok, Jeffrey
%A Morgan, Jeffrey
%A Wen, Patrick
%A Demetri, George
%A Coffman, Robert L.
%A Nadler, Lee M.
%J Clinical cancer research : an official journal of the American Association for Cancer Research
%D 2008
%8 Sep 01
%V 14
%N 17
%@ 1078-0432
%G eng
%F Haining2008
%X CpG oligodeoxynucleotides (CpG-ODN) are being investigated as cancer vaccine adjuvants because they mature plasmacytoid dendritic cells (PDC) into potent antigen-presenting cells. CpG-ODN also induce PDC to secrete chemokines that alter lymphocyte migration. Whether CpG-ODN TLR signals enhance antigen-specific immunity and/or trafficking in humans is unknown.
%K Adjuvants, Immunologic
%K Cancer Vaccines
%K Cell Movement
%K Dendritic Cells
%K Granulocyte-Macrophage Colony-Stimulating Factor
%K Humans
%K Oligodeoxyribonucleotides
%K T-Lymphocytes
%K Telomerase
%K Toll-Like Receptor 9
%K Vaccines, Subunit
%U http://dx.doi.org/10.1158/1078-0432.CCR-08-0526
%U http://www.ncbi.nlm.nih.gov/pubmed/18765557
%P 5626-5634

PT Journal
AU Haining, WN
   Davies, J
   Kanzler, H
   Drury, L
   Brenn, T
   Evans, J
   Angelosanto, J
   Rivoli, S
   Russell, K
   George, S
   Sims, P
   Neuberg, D
   Li, X
   Kutok, J
   Morgan, J
   Wen, P
   Demetri, G
   Coffman, RL
   Nadler, LM
TI CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.
SO Clinical cancer research : an official journal of the American Association for Cancer Research
JI Clin. Cancer Res.
PD Sep
PY 2008
BP 5626
EP 5634
VL 14
IS 17
DI 10.1158/1078-0432.CCR-08-0526
LA eng
DE Adjuvants, Immunologic; Cancer Vaccines; Cell Movement; Dendritic Cells; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Oligodeoxyribonucleotides; T-Lymphocytes; Telomerase; Toll-Like Receptor 9; Vaccines, Subunit
AB CpG oligodeoxynucleotides (CpG-ODN) are being investigated as cancer vaccine adjuvants because they mature plasmacytoid dendritic cells (PDC) into potent antigen-presenting cells. CpG-ODN also induce PDC to secrete chemokines that alter lymphocyte migration. Whether CpG-ODN TLR signals enhance antigen-specific immunity and/or trafficking in humans is unknown.
ER

PMID- 18765557
OWN - NLM
STAT- MEDLINE
DA  - 20080903
DCOM- 20081003
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 14
IP  - 17
DP  - 2008 Sep 1
TI  - CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in
      humans.
PG  - 5626-34
LID - 10.1158/1078-0432.CCR-08-0526 [doi]
AB  - PURPOSE: CpG oligodeoxynucleotides (CpG-ODN) are being investigated as cancer
      vaccine adjuvants because they mature plasmacytoid dendritic cells (PDC) into
      potent antigen-presenting cells. CpG-ODN also induce PDC to secrete chemokines
      that alter lymphocyte migration. Whether CpG-ODN TLR signals enhance
      antigen-specific immunity and/or trafficking in humans is unknown. EXPERIMENTAL
      DESIGN: We conducted a phase I study of CpG-ODN (1018 ISS) given as a vaccine
      adjuvant with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce
      T-cell immunity to a peptide vaccine from the tumor-associated antigen hTERT.
      RESULTS: The adjuvant effect was limited; only 1 of 16 patients showed a
      high-frequency hTERT-specific tetramer CD8(+) T-cell response. However, CpG-ODN
      induced marked, transient peripheral blood lymphopenia. Biopsies showed dense
      lymphocytic infiltration at the vaccine site clustered around activated PDC. In
      vitro, CpG-ODN-treated PDC induced T-cell migration, showing that CpG-ODN
      stimulation of human PDC was sufficient to chemoattract T cells. CONCLUSIONS: Our
      results show that (a) CpG-ODN with GM-CSF may not be an effective adjuvant
      strategy for hTERT peptide vaccines but (b) GM-CSF/CpG-ODN causes a PDC-mediated 
      chemokine response that recruits T-cell migration to the peripheral tissues.
      These findings suggest a novel therapeutic role for targeted injections of
      CpG-ODN to direct lymphocyte migration to specific sites such as the tumor bed.
FAU - Haining, W Nicholas
AU  - Haining WN
AD  - Department of Hematology/Oncology, Children's Hospital, Dana-Farber Cancer
      Institute, Boston, MA 02115, USA.
FAU - Davies, Jeffrey
AU  - Davies J
FAU - Kanzler, Holger
AU  - Kanzler H
FAU - Drury, Linda
AU  - Drury L
FAU - Brenn, Thomas
AU  - Brenn T
FAU - Evans, John
AU  - Evans J
FAU - Angelosanto, Jill
AU  - Angelosanto J
FAU - Rivoli, Steven
AU  - Rivoli S
FAU - Russell, Kate
AU  - Russell K
FAU - George, Suzanne
AU  - George S
FAU - Sims, Paul
AU  - Sims P
FAU - Neuberg, Donna
AU  - Neuberg D
FAU - Li, Xiaochun
AU  - Li X
FAU - Kutok, Jeffrey
AU  - Kutok J
FAU - Morgan, Jeffrey
AU  - Morgan J
FAU - Wen, Patrick
AU  - Wen P
FAU - Demetri, George
AU  - Demetri G
FAU - Coffman, Robert L
AU  - Coffman RL
FAU - Nadler, Lee M
AU  - Nadler LM
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for
      Cancer Research
JID - 9502500
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (CPG-oligonucleotide)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Oligodeoxyribonucleotides)
RN  - 0 (TLR9 protein, human)
RN  - 0 (Toll-Like Receptor 9)
RN  - 0 (Vaccines, Subunit)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - EC 2.7.7.49 (TERT protein, human)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Cancer Vaccines/adverse effects/*therapeutic use
MH  - Cell Movement
MH  - Dendritic Cells/*immunology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/*immunology
MH  - Humans
MH  - Oligodeoxyribonucleotides/immunology/*therapeutic use
MH  - T-Lymphocytes/*immunology
MH  - Telomerase/*immunology
MH  - Toll-Like Receptor 9/antagonists & inhibitors
MH  - Vaccines, Subunit/*therapeutic use
EDAT- 2008/09/04 09:00
MHDA- 2008/10/04 09:00
CRDT- 2008/09/04 09:00
AID - 14/17/5626 [pii]
AID - 10.1158/1078-0432.CCR-08-0526 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2008 Sep 1;14(17):5626-34. doi: 10.1158/1078-0432.CCR-08-0526.
TY  - JOUR
AU  - Haining, W. Nicholas
AU  - Davies, Jeffrey
AU  - Kanzler, Holger
AU  - Drury, Linda
AU  - Brenn, Thomas
AU  - Evans, John
AU  - Angelosanto, Jill
AU  - Rivoli, Steven
AU  - Russell, Kate
AU  - George, Suzanne
AU  - Sims, Paul
AU  - Neuberg, Donna
AU  - Li, Xiaochun
AU  - Kutok, Jeffrey
AU  - Morgan, Jeffrey
AU  - Wen, Patrick
AU  - Demetri, George
AU  - Coffman, Robert L.
AU  - Nadler, Lee M.
PY  - 2008/Sep/01
TI  - CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.
T2  - Clin. Cancer Res.
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
SP  - 5626
EP  - 5634
VL  - 14
IS  - 17
KW  - Adjuvants, Immunologic
KW  - Cancer Vaccines
KW  - Cell Movement
KW  - Dendritic Cells
KW  - Granulocyte-Macrophage Colony-Stimulating Factor
KW  - Humans
KW  - Oligodeoxyribonucleotides
KW  - T-Lymphocytes
KW  - Telomerase
KW  - Toll-Like Receptor 9
KW  - Vaccines, Subunit
N2  - CpG oligodeoxynucleotides (CpG-ODN) are being investigated as cancer vaccine adjuvants because they mature plasmacytoid dendritic cells (PDC) into potent antigen-presenting cells. CpG-ODN also induce PDC to secrete chemokines that alter lymphocyte migration. Whether CpG-ODN TLR signals enhance antigen-specific immunity and/or trafficking in humans is unknown.
SN  - 1078-0432
UR  - http://dx.doi.org/10.1158/1078-0432.CCR-08-0526
UR  - http://www.ncbi.nlm.nih.gov/pubmed/18765557
ID  - Haining2008
ER  - 
<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
<b:Source>
<b:Tag>Haining2008</b:Tag>
<b:SourceType>ArticleInAPeriodical</b:SourceType>
<b:Year>2008</b:Year>
<b:Month>Sep</b:Month>
<b:Day>1</b:Day>
<b:PeriodicalName>Clinical cancer research : an official journal of the American Association for Cancer Research</b:PeriodicalName>
<b:Volume>14</b:Volume>
<b:Issue>17</b:Issue>
<b:Pages>5626-5634</b:Pages>
<b:Author>
<b:Author><b:NameList>
<b:Person><b:Last>Haining</b:Last><b:First>W</b:First><b:Middle>Nicholas</b:Middle></b:Person>
<b:Person><b:Last>Davies</b:Last><b:First>Jeffrey</b:First></b:Person>
<b:Person><b:Last>Kanzler</b:Last><b:First>Holger</b:First></b:Person>
<b:Person><b:Last>Drury</b:Last><b:First>Linda</b:First></b:Person>
<b:Person><b:Last>Brenn</b:Last><b:First>Thomas</b:First></b:Person>
<b:Person><b:Last>Evans</b:Last><b:First>John</b:First></b:Person>
<b:Person><b:Last>Angelosanto</b:Last><b:First>Jill</b:First></b:Person>
<b:Person><b:Last>Rivoli</b:Last><b:First>Steven</b:First></b:Person>
<b:Person><b:Last>Russell</b:Last><b:First>Kate</b:First></b:Person>
<b:Person><b:Last>George</b:Last><b:First>Suzanne</b:First></b:Person>
<b:Person><b:Last>Sims</b:Last><b:First>Paul</b:First></b:Person>
<b:Person><b:Last>Neuberg</b:Last><b:First>Donna</b:First></b:Person>
<b:Person><b:Last>Li</b:Last><b:First>Xiaochun</b:First></b:Person>
<b:Person><b:Last>Kutok</b:Last><b:First>Jeffrey</b:First></b:Person>
<b:Person><b:Last>Morgan</b:Last><b:First>Jeffrey</b:First></b:Person>
<b:Person><b:Last>Wen</b:Last><b:First>Patrick</b:First></b:Person>
<b:Person><b:Last>Demetri</b:Last><b:First>George</b:First></b:Person>
<b:Person><b:Last>Coffman</b:Last><b:First>Robert</b:First><b:Middle>L</b:Middle></b:Person>
<b:Person><b:Last>Nadler</b:Last><b:First>Lee</b:First><b:Middle>M</b:Middle></b:Person>
</b:NameList></b:Author>
</b:Author>
<b:Title>CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.</b:Title>
 <b:ShortTitle>Clin. Cancer Res.</b:ShortTitle>
<b:Comments>CpG oligodeoxynucleotides (CpG-ODN) are being investigated as cancer vaccine adjuvants because they mature plasmacytoid dendritic cells (PDC) into potent antigen-presenting cells. CpG-ODN also induce PDC to secrete chemokines that alter lymphocyte migration. Whether CpG-ODN TLR signals enhance antigen-specific immunity and/or trafficking in humans is unknown.</b:Comments>
</b:Source>
</b:Sources>